Two former CEOs of Global Discovery Bioscience Corp. are facing legal ramifications due to accusations that they diverted resources to another company, thereby inhibiting promising opportunities for new medical tests. This decision has been confirmed by a judge from the Delaware Chancery Court. The executives’ attempted dismissal of the claims has been unsuccessful.
The allegations contend that the actions undertaken by the executives deprived Global Discovery Biosciences Corp. of its potential progress in the medical field. Although the specifics of the resources allegedly transferred and the exact impact they had on the corporation’s potential developments have not been elaborated on, the legal implications for such claims are significant.
It’s emblematic of increasing challenges corporations face in the protection of proprietary technologies and ideas from internal threats, as much as from external competitors. The case remains ongoing and its developments can be followed on Law360.